tiprankstipranks
Advertisement
Advertisement

TSE:RVV Stock Latest News

Revive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses
Company AnnouncementsRevive Extends Bucillamine Patent Shield Across Nerve-Agent and Infectious Disease Uses
1M ago
Revive Therapeutics announces North American patent filings for bucillamine
PremiumThe Fly
Revive Therapeutics announces North American patent filings for bucillamine
1M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany Announcements
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
4M ago
Revive Therapeutics provides update on nerve agent countmeasure study
PremiumThe Fly
Revive Therapeutics provides update on nerve agent countmeasure study
4M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany Announcements
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
5M ago
Revive Therapeutics says nerve agent countmeasure study ‘remains in progress’
PremiumThe FlyRevive Therapeutics says nerve agent countmeasure study ‘remains in progress’
5M ago
Revive Therapeutics Closes Second Tranche of Private Placement
Premium
Company Announcements
Revive Therapeutics Closes Second Tranche of Private Placement
7M ago
Revive Therapeutics Extends Private Placement to Support Therapeutic Programs
Premium
Company Announcements
Revive Therapeutics Extends Private Placement to Support Therapeutic Programs
7M ago
Revive Therapeutics Completes First Tranche of Private Placement and Debt Settlement
PremiumCompany Announcements
Revive Therapeutics Completes First Tranche of Private Placement and Debt Settlement
8M ago
Revive Therapeutics Announces Private Placement and Debt Settlement Plan
PremiumCompany Announcements
Revive Therapeutics Announces Private Placement and Debt Settlement Plan
9M ago
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
PremiumCompany Announcements
Revive Therapeutics Updates on Nerve Agent Countermeasure Study
9M ago
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
PremiumCompany Announcements
Revive Therapeutics Advances Nerve Agent Countermeasure Study with Canadian Defence
10M ago
Revive Therapeutics nears completion of nerve agent countermeasure study
PremiumThe FlyRevive Therapeutics nears completion of nerve agent countermeasure study
10M ago
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
Premium
Company Announcements
Revive Therapeutics Advances Next-Gen Bucillamine for Critical Medical Needs
10M ago
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
Premium
Company Announcements
Revive Therapeutics Advances Bucillamine Research for Nerve Agent Exposure
11M ago
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
PremiumCompany Announcements
Revive Therapeutics Announces Shares for Debt Transaction to Preserve Cash
12M ago
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
PremiumThe Fly
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial
1y ago
ATAI
CMND
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
PremiumCompany Announcements
Revive Therapeutics Explores Bucillamine’s Role in Cancer Treatment
1y ago
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
PremiumThe Fly
Revive Therapeutics to investigate Bucillamine’s potential in cancer treatment
1y ago
Revive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
PremiumCompany AnnouncementsRevive Therapeutics Expands Pipeline with Molecular Hydrogen Acquisition
1y ago
Revive enters asset purchase agreement for molecular hydrogen program
Premium
The Fly
Revive enters asset purchase agreement for molecular hydrogen program
1y ago
Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
Premium
Company Announcements
Revive Therapeutics Aligns with Shareholders in Annual Meeting Decisions
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >